RE:RE:RE:Meetings with institutional investors and analystsThe reason they are not permitted to release the deal figures in full display for us is because Abbvie/Allergan continue to negotiate deals in other veins of their business and simply do not want anything to influence those negotiations. They may not do that for every deal but common sense dictates that if they do invoke it, its for a darn good reason. Good for us.
Hence, that is the reason there is inherent value when they brought in Linda, because she simply knows what is what in the world of negotiating pricing in this space.
But in essence, the share price today is a reflection of consensus of what the deal is worth when in fact it is just one big fat giant guess, pure and simple. We are all wrong, in essence.
I think the market is placing more emphasis in the CEOs historical track record than Linda's ability to settle on decent and fair terms. I am not sure the R&F agreement would appear the way it does or if we would even have an agreement at all if she was at the table then. It is also possible she would have advised them to take it as a loss leader to get other's attention and use it to develop the logistics and manufacturing part.
So for these reasons I don't subscribe to the doom and gloom, at all.
Its just one big set of assumptions that will in the end make a$$'s of all of us.